Oncology Technology Solutions, Services Impacting Patients and Providers
Georgiamune and Verily Partner to Advance Novel Cancer Treatment
What You Should Know: - Georgiamune, a privately held, clinical stage biotechnology company, and Verily, an Alphabet precision health technology company forms a strategic partnership to advance novel therapeutics for patients with cancer. - Through this partnership, Verily and Georgimune will focus on identifying the patient population that could potentially benefit the most from Georgiamune’s GIM-122, a first-in-class dual-functioning antibody that has the potential to help patients with
Read More
Penn Medicine Taps Flatiron Health for Advanced Cancer Care
What You Should Know: Flatiron Health today announced a new agreement to bring Flatiron Assist™ advanced cancer care insights to oncology care clinicians at Penn Medicine’s Abramson Cancer Center (ACC).The collaboration between Flatiron Health and Penn Medicine will focus on further enabling clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN
Read More
Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment
What You Should Know: Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its partnership with patient-centric advocacy organization FibroFighters to advance treatment for fibrolamellar carcinoma (FLC) patients.Fibrolamellar carcinoma (FLC) is a rare liver cancer that typically presents in young adolescents and young adults at a median age of 22 who have no history of liver disease. There is no clear standard of care for the disease, and in
Read More
FDA Selects Ontada to Investigate Rare Cancers Treated in US Community Oncology Setting
What You Should Know: Ontada, announced it was awarded a competitive contract with the U.S. Food and Drug Administration (FDA) to advance the use of real-world data (RWD) in the U.S. community oncology setting.Ontada will conduct real-world research (RWR) that aims to strengthen the scientific understanding of the natural history of rare cancers by leveraging Ontada’s community oncology footprint and unique RWD. Study Goals & Objectives The goal of the study is to
Read More
Ibex Medical Analytics Raises $55M to Drive AI for Cancer Diagnosis Adoption Globally
What You Should Know: – Ibex Medical Analytics (Ibex), a provider of AI-powered cancer diagnostics raises $55M in Series C financing round led by 83North. - The round also included participation from Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital. The financing brings total funding to over $100M since Ibex’s inception in 2016.
Read More
Oncology Software: The Digital Backbone of Cancer Care
The complex and dynamic landscape of multimodal cancer care is boosting demand for oncology-specific technological innovations. The need for elevated cancer care is steadily climbing, compelling software developers to create increasingly integrated and sophisticated solutions. Oncology has always been at the forefront of digitization due to the substantial amount of data needed and generated for each patient during the treatment process. Today, advanced oncology software offers clinicians a
Read More
PicnicHealth Enters Oncology Real-World Data Market
What You Should Know: PicnicHealth, a patient-centered health technology company, today announced its entry into the real-world data market for oncology.Drawing from its success working with chronic disease patients to create robust datasets, the company aims to advance oncology research using a similar model by working directly with people living with cancer to collect and structure their medical records data. PicnicHealth is actively exploring partnerships to develop new patient
Read More
Finance: Elevation Oncology Announces Pricing of $50M IPO
What You Should Know: Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced the pricing of an underwritten public offering of (i) 17,810,000 shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 4,440,000
Read More
Why AI-Driven Cancer Screening Will Soon Become Standard of Care
Healthcare delivery is undergoing a dramatic transformation as AI technologies begin to take hold in the care setting. The technology is revolutionizing radiology, particularly in ED triage, early disease detection, and now in cancer imaging and reporting. These fields are particularly suited to improvements using AI, given their antiquated workflows and resistance to change over the decades. But how – specifically – is AI transforming this industry for good? Using AI for advanced
Read More
